NCT04399577View on ClinicalTrials.gov

Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

March 3, 2019

Study Completion Date

September 3, 2019

Conditions
Warts
Interventions
BIOLOGICAL

Candida antigen

Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention

Trial Locations (1)

44519

Zagazig University Faculty of Medicine, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT04399577 - Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts | Biotech Hunter | Biotech Hunter